📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
Latest filing: 2026-09-14 16:21
122 analysed today
FollowTelegram
122
Today
149,523
All-time analysed
42,890
Positive
6,652
Negative
91,308
Neutral
8,605
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
11 announcements match the current filters (relevance ≥ 5).
Shivalik Rasayan Allots Shares & Warrants to Raise ₹30.75 Cr at ₹250/Share
Shivalik Rasayan's board approved the allotment of 2,82,000 equity shares at ₹250 per share (₹7.05 crore) to public investors and 9,47,990 fully convertible warrants at ₹250 per warrant (₹23.70 crore) to promoters and public entities. The combined preferential issue totals ₹30.75 crore, which represents roughly 3.8% of the company's ₹819 crore market capitalization. Promoter entity Growel Remedies received 4,28,000 warrants, while the rest went to public investors. Upon full dilution and conversion of warrants, paid-up equity share capital will increase to ₹8.49 crore across 1,69,80,355 equity shares.
Confidence: HIGH
What changedThe board formally allotted 2.82 lakh equity shares and 9.48 lakh convertible warrants on a preferential basis, expanding immediate and diluted share capital.
Why it mattersProvides ₹30.75 crore in equity funding to bolster the balance sheet and support operations, though it introduces an equity dilution of ~7.8% relative to the prior base.
Total fundraise value: Rs. 30,74,97,500Issue price per share/warrant: Rs. 250Fundraise vs Market Cap: ~3.8%Fully diluted shares: 1,69,80,355
📅 Short termNeutral to slightly muted due to equity dilution and the issue price being at a discount to the current market price of ₹362.1.
📈 Long termStrengthens capital reserves for working capital and API project commercialization, supporting the company's low-debt profile.
⚠ Risk flags
- Equity dilution of ~7.8% on a fully diluted basis
- Pricing discount compared to prevailing market prices
Key Highlights
Allotment of 2,82,000 equity shares at ₹250 each, raising ₹7.05 crore from public investors
Allotment of 9,47,990 convertible warrants at ₹250 each, totaling ₹23.70 crore across promoter and public entities
Promoter group entity Growel Remedies allotted 4,28,000 warrants (45.1% of warrant issue)
Paid-up equity capital rises to ₹8,01,61,825 immediately and ₹8,49,01,775 on a fully diluted basis
Issue price of ₹250 is at an approximate 31% discount to the current market price of ₹362.1
👀 What to Watch
Track the deployment timeline of the raised funds toward the Dahej expansion/API filings and monitor the exercise of warrants within the statutory 18-month window.
Shivalik Rasayan Shareholders Approve Preferential Issue of 3.72L Shares & 9.48L Warrants
Shivalik Rasayan Limited announced the voting results of its Extra-Ordinary General Meeting held on August 20, 2026. Shareholders approved two special resolutions with over 99.99% majority. Resolution 1 approved the issuance of up to 3,72,000 equity shares to public investors on a preferential basis, while Resolution 2 approved the issuance of up to 9,48,000 fully convertible warrants to both promoter and public categories. In aggregate, these proposals represent up to 13.20 lakh shares, or approximately 8.38% of current outstanding equity capital.
Confidence: HIGH
What changedShareholders officially passed special resolutions approving preferential allotments of equity shares and convertible warrants.
Why it mattersThe fundraise provides capital for ongoing growth initiatives (such as capacity integration and API filings), while introducing an 8.38% potential equity dilution.
Equity shares approved: 3,72,000Convertible warrants approved: 9,48,000Total potential new shares: 13,20,000Potential equity dilution: ~8.38%EGM Date: 20.08.2026
📅 Short termFormalizes shareholder backing for the preferential issue, clearing the regulatory path for board allotment.
📈 Long termCapital raised via equity and warrant conversion will strengthen the balance sheet to fund ongoing validation and export initiatives.
⚠ Risk flags
- Equity dilution of ~8.38% upon full warrant conversion
- Pricing terms and end-use details not specified in this voting extract
Key Highlights
Resolution 1 passed with 99.9989% approval for issuing up to 3,72,000 equity shares to public category on preferential basis
Resolution 2 passed with 99.9997% approval for issuing up to 9,48,000 fully convertible warrants to promoter and public categories
Total potential issuance of 13.20 lakh shares represents ~8.38% dilution on existing equity base of 15,750,365 shares
A total of 88,47,040 votes were polled out of 15,750,365 total shares, representing 56.17% voter participation
👀 What to Watch
Track subsequent disclosures on issue price, total capital raised, allotment confirmation, and deployment of proceeds toward API or agrochemical business expansion.
EGM Approves Preferential Issue of 3.72L Shares and 9.48L Convertible Warrants
Shivalik Rasayan shareholders have approved the preferential issuance of up to 3,72,000 equity shares to public investors and up to 9,48,000 fully convertible warrants to promoters and public investors. Both special resolutions passed with over 99.99% of votes cast in favor at the EGM held on August 20, 2026. The total potential issuance of 13.20 lakh shares/warrants represents approximately 8.1% of the company's 1.63 crore voting share base.
Confidence: HIGH
What changedShareholders formally approved the preferential allotment of up to 3.72 lakh equity shares and 9.48 lakh convertible warrants.
Why it mattersThe capital infusion will provide growth equity to fund business operations and API/agrochemical initiatives, while bringing ~8.1% potential dilution.
Equity shares to be issued: 3,72,000Convertible warrants to be issued: 9,48,000Total shares polled: 1,63,08,717Potential equity dilution: ~8.1%
📅 Short termClear regulatory and shareholder overhang for the fundraise; watch for allotment notifications and pricing disclosure.
📈 Long termStrengthens capital structure to support ongoing agrochemical and API expansion pipelines, with promoter participation signaling insider commitment.
⚠ Risk flags
- Equity dilution of ~8.1% upon full warrant conversion
- Issue price and fund usage specifics not detailed in the scrutinizer report
Key Highlights
Approved preferential issue of up to 3,72,000 equity shares to the public category with 99.999% votes in favor.
Approved preferential issue of up to 9,48,000 fully convertible warrants to promoter and public categories with 99.999% votes in favor.
Total votes polled across resolutions stood at 1,63,08,717 shares.
Combined potential issue size represents ~8.1% dilution on the existing 1.63 crore share capital.
👀 What to Watch
Track the upcoming board allotment notice for issue pricing, total funds to be raised, and timelines for warrant subscription and conversion.
Shivalik Rasayan EGM Considers Issue of 3.72L Shares and 9.48L Convertible Warrants
Shivalik Rasayan Limited conducted an Extra-Ordinary General Meeting (EGM) on August 20, 2026, to seek shareholder approval for preferential capital issuance. The proposals include issuing up to 3,72,000 equity shares to public investors and up to 9,48,000 fully convertible warrants to promoter and public categories. Together, the potential 13.20 lakh shares/warrants represent around 5.8% dilution on the existing equity base. Voting results will be submitted separately upon receipt of the scrutinizer's report.
Confidence: HIGH
What changedShareholders considered and voted on special resolutions to issue 3.72 lakh equity shares and 9.48 lakh convertible warrants on a preferential basis.
Why it mattersThe preferential issuance will inject equity capital to support the company's agrochemical and API business expansion, resulting in minor equity dilution (~5.8%).
Preferential Equity Shares: up to 3,72,000Preferential Convertible Warrants: up to 9,48,000EGM Date: August 20, 2026
📅 Short termMarket focus will remain on the disclosure of the official voting outcome and preferential issue pricing/proceeds.
📈 Long termCapital raised will provide balance sheet support for ongoing API filings and capacity utilization across facilities.
⚠ Risk flags
- Equity dilution of ~5.8% upon full warrant conversion
- Final pricing and exact quantum of funds raised not disclosed in the proceedings filing
Key Highlights
Special Resolution proposed for issuance of up to 3,72,000 equity shares to the 'Public' category on a preferential basis
Special Resolution proposed for issuance of up to 9,48,000 fully convertible warrants to 'Promoter and Promoter Group' and 'Public' categories
Remote e-voting window was open from August 17, 2026 (9:00 AM) to August 19, 2026 (5:00 PM)
Combined voting results (remote e-voting and EGM poll) will be declared following the Scrutinizer's report
👀 What to Watch
Track the upcoming scrutinizer's report for final voting results and subsequent filings on allotment price, issue pricing details, and fund deployment plans.
Shivalik Rasayan Q1 Cons PAT Rises 59.5% YoY to ₹4.50 Cr; Final Dividend of ₹0.50
Shivalik Rasayan reported consolidated net sales of ₹96.34 cr for Q1 FY27 (quarter ended June 30, 2026), marking a 7.87% YoY increase from ₹89.31 cr in Q1 FY26, though down 6.30% sequentially from ₹102.82 cr. Consolidated net profit grew 59.54% YoY to ₹4.50 cr compared to ₹2.82 cr in the corresponding quarter last year, while declining from ₹7.17 cr in Q4 FY26. Basic EPS stood at ₹2.16 versus ₹1.02 in Q1 FY26. Additionally, the Board recommended a final dividend of ₹0.50 (10%) per equity share of face value ₹5 for FY26, subject to shareholder approval at the AGM on September 28, 2026.
Confidence: HIGH
What changedReported Q1 FY27 financial performance showing robust YoY bottom-line growth and fixed AGM/dividend dates.
Why it mattersDemonstrates margin resilience driven by Agrochemicals and Pharma Formulations despite persistent operating drag in the standalone API business.
Consolidated Net Sales: ₹96.34 crConsolidated PAT: ₹4.50 crYoY PAT Growth: +59.54%Dividend per share: ₹0.50Q1 Revenue vs TTM Revenue: ~26.2%
📅 Short termEarnings show operational stability on a YoY basis; stock may see positive sentiment on margin expansion despite sequential softness.
📈 Long termGrowth hinges on commercialization of the 20 validated API molecules and capacity utilization at the expanded Dahej facilities.
⚠ Risk flags
- Persistent operating losses in the API business segment (-₹1.98 cr in Q1).
- Sequential revenue and profit contraction compared to Q4 FY26.
Key Highlights
Consolidated revenue from operations rose 7.87% YoY to ₹96.34 cr (₹9,633.85 lakhs) vs ₹89.31 cr in Q1 FY26.
Consolidated PAT expanded 59.54% YoY to ₹4.50 cr (₹450.13 lakhs) from ₹2.82 cr in Q1 FY26.
Agrochemicals segment delivered ₹43.83 cr revenue and ₹6.31 cr segment profit, while API reported a segment loss of ₹1.98 cr.
Proposed final dividend of ₹0.50 per share (10%), with book closure set from September 22 to September 28, 2026.
👀 What to Watch
Track turnaround and commercial ramp-up in the API segment which continues to report operating losses, alongside export filings traction from oncology validations.
Shivalik Rasayan to Raise Rs 9.30 Cr via Preferential Issue; EGM Scheduled for Aug 20
Shivalik Rasayan Limited has convened an Extraordinary General Meeting (EGM) on August 20, 2026, to seek shareholder approval for a preferential issue of 3,72,000 equity shares at Rs 250 per share, totaling Rs 9.30 crore. The company also proposes issuing 9,48,000 fully convertible warrants to both Promoter and Public categories. The equity issue price of Rs 250 represents a slight discount to the current market price of Rs 259.9. Notably, Non-Executive Director Ashwani Kumar Sharma is a proposed allottee for 1,32,000 shares.
Confidence: HIGH
What changedThe company is initiating a small-scale capital infusion through a mix of equity shares for public investors and convertible warrants for both promoters and public participants.
Why it mattersWhile the fundraise is small relative to the Rs 619 Cr market cap, the participation of a director and promoters in the warrant issuance indicates internal alignment, though it will lead to minor equity dilution.
Equity Issue Value: Rs 9.30 CrIssue Price: Rs 250Total Warrants to be Issued: 9,48,000 unitsFundraise vs Market Cap: ~1.5%Director Allotment (A.K. Sharma): 1,32,000 shares
📅 Short termThe stock may see range-bound movement as the issue price (Rs 250) is close to the current market price (Rs 259.9), providing a floor but also signaling limited immediate premium.
📈 Long termLimited structural impact given the small size of the raise; however, successful conversion of warrants in the future could provide a secondary capital buffer for their 250% capacity expansion plans.
⚠ Risk flags
- Minor equity dilution
- Related-party participation (Director as allottee)
- Specific end-use of funds not detailed in the summary
Key Highlights
Preferential allotment of up to 3,72,000 equity shares at a fixed price of Rs 250 per share
Total equity fundraise amount of Rs 9.30 crore, representing approximately 1.5% of current market capitalization
Proposed issuance of 9,48,000 fully convertible warrants to Promoters and Public entities
Relevant date for determining the minimum issue price set as July 21, 2026
EGM to be held on August 20, 2026, with remote e-voting from August 17 to August 19
👀 What to Watch
Investors should monitor the EGM voting results and the subsequent disclosure regarding the specific end-use of these funds to see if they support the company's ongoing API and Agrochemical capacity expansions.
Rs 33 Cr fundraise via preferential issue of shares and warrants at Rs 250 per share
Shivalik Rasayan's board has approved a total fundraise of Rs 33 crore through a mix of equity shares and convertible warrants. The company will issue 3.72 lakh equity shares to public investors (Rs 9.3 cr) and 9.48 lakh warrants to both promoters and public investors (Rs 23.7 cr). The issue price of Rs 250 represents a ~3.4% premium to the current market price of Rs 241.7. This capital infusion represents approximately 5.7% of the company's current market capitalization.
Confidence: HIGH
What changedThe company is initiating a fresh capital raise of Rs 33 crore, involving a mix of immediate equity and deferred equity (warrants) with participation from both promoters and public investors.
Why it mattersThe fundraise strengthens the company's net worth (currently Rs 405 Cr) and provides liquidity to support its 250% capacity expansion in Agrochemicals and the validation of 20 new APIs for regulated markets.
Total Fundraise Value: Rs 33.00 CrIssue Price per Share: Rs 250Fundraise vs Market Cap: ~5.7%Promoter Warrant Subscription: 4,28,000 unitsEGM Date: August 20, 2026
📅 Short termThe announcement is likely to be viewed positively by the market as the issue price is at a premium to the current market price and includes promoter participation, signaling internal confidence.
📈 Long termThe capital infusion supports the company's structural shift toward high-margin Oncology APIs and expanded Agrochemical capacity, though it results in a ~5.5% equity dilution.
⚠ Risk flags
- Equity dilution of approximately 5.5% for existing shareholders
- Utilization of funds not specifically detailed in the board outcome
Key Highlights
Total fundraise of Rs 33 crore approved via preferential allotment of shares and warrants
Issue price fixed at Rs 250 per unit, which is a premium over the current market price of Rs 241.7
Promoter entity Growel Remedies Limited to subscribe to 4.28 lakh warrants (approx. 45% of total warrants)
Warrants are convertible into equity shares within a maximum period of 18 months from allotment
Extra-Ordinary General Meeting (EGM) scheduled for August 20, 2026, to seek shareholder approval
👀 What to Watch
Investors should monitor the EGM outcome on August 20, 2026, and watch for specific disclosures regarding the utilization of these funds, particularly if they are directed toward the Dahej Unit-I API facility or debt reduction.
Rs 33 Cr Fundraise: Shivalik Rasayan to Issue Shares and Warrants at Rs 250
Shivalik Rasayan's board has approved a total fundraise of Rs 33 crore through a preferential issue of equity shares and convertible warrants. The company will issue 3.72 lakh equity shares to public investors (Rs 9.3 cr) and 9.48 lakh warrants to promoters and public entities (Rs 23.7 cr). The issue price of Rs 250 per unit is at a ~3.4% premium to the current market price of Rs 241.7. This capital infusion represents approximately 5.7% of the company's current market capitalization.
Confidence: HIGH
What changedThe company is initiating a fresh equity capital raise involving both promoters and public investors, moving to strengthen its balance sheet for growth.
Why it mattersThe fundraise provides necessary liquidity to support the company's expansion into high-margin Oncology APIs and the ramp-up of its 5,000 MTPA Dimethoate technical capacity without increasing debt significantly.
Total Fundraise: Rs 33.00 CrIssue Price: Rs 250Fundraise vs Market Cap: ~5.7%Promoter Warrant Subscription: 4,28,000 unitsEstimated Dilution: ~5.2%
📅 Short termThe announcement is likely to be viewed positively as the issue price is at a premium to the current market price, indicating investor and promoter confidence.
📈 Long termThe capital will support the structural shift toward regulated API markets (US/Europe/Japan), which is critical for the company's long-term margin improvement strategy.
⚠ Risk flags
- Equity dilution of approximately 5.2% for existing shareholders
- Execution risk in scaling the API business to meet US FDA standards
Key Highlights
Total fundraise of Rs 33 crore via preferential allotment of equity and warrants
Issue price fixed at Rs 250 per share, which is higher than the current market price of Rs 241.7
Promoter entity Growel Remedies Limited to subscribe to 4.28 lakh warrants (approx. Rs 10.7 cr)
Warrants are convertible into equity shares within a maximum period of 18 months
Extra-Ordinary General Meeting (EGM) for shareholder approval scheduled for August 20, 2026
👀 What to Watch
Investors should watch for the shareholder approval at the EGM on August 20 and subsequent updates on how this capital will be deployed toward the company's 250% capacity expansion and API filings.
Shivalik Rasayan FY26 Revenue Up 16% to ₹372 Cr; Net Profit Declines 12%; ₹0.50 Dividend Declared
Shivalik Rasayan reported a 16.2% year-on-year growth in consolidated revenue to ₹372.08 crore for FY26, driven primarily by the Pharma Formulation and API segments. However, consolidated net profit declined by 12% to ₹17.97 crore, impacted by lower margins in the Agrochemicals segment and higher operational expenses. The board has recommended a final dividend of ₹0.50 per share (10% of face value). Additionally, the company saw the resignation of a non-executive director and a change in its internal auditor.
Key Highlights
Consolidated Total Revenue grew 16.2% YoY to ₹37,208.09 Lakhs in FY26.
Consolidated Net Profit fell 12% YoY to ₹1,796.88 Lakhs, with EPS dropping to ₹7.71 from ₹10.60.
Pharma Formulation segment revenue increased by 21.6% YoY to ₹19,776.97 Lakhs.
Agrochemicals segment profit witnessed a decline of 23% YoY to ₹2,202.11 Lakhs.
Board recommended a final dividend of ₹0.50 per equity share for the financial year 2025-26.
👀 What to Watch
Investors should monitor the margin pressure in the Agrochemicals business and the progress of the API segment's path to profitability. While revenue growth is healthy, the decline in bottom-line performance and management/auditor changes suggest a 'Watch' approach.
Shivalik Rasayan Q3 Net Profit Drops 47% YoY to ₹3.67 Crore; Revenue Down 4%
Shivalik Rasayan reported a weak set of numbers for Q3 FY26, with consolidated net profit declining significantly by 47% YoY to ₹3.67 crore. Total revenue saw a moderate decline of 4.2% YoY to ₹83.21 crore, primarily dragged down by the Agrochemicals and API segments. The API segment continues to be a drag on profitability, reporting a segment loss of ₹2.57 crore for the quarter. While Pharma Formulations showed slight growth, the overall margin contraction across segments led to a sharp drop in earnings per share from ₹3.39 to ₹1.71.
Key Highlights
Consolidated Net Profit fell 47.1% YoY to ₹3.67 crore from ₹6.94 crore in the previous year's quarter.
Total Revenue from operations decreased by 4.2% YoY to ₹83.21 crore compared to ₹86.91 crore.
The API segment reported an operating loss of ₹2.57 crore, widening from a loss of ₹1.75 crore YoY.
Agrochemicals revenue declined significantly to ₹28.10 crore from ₹37.85 crore in Q3 FY25.
Consolidated Basic EPS for the quarter dropped to ₹1.71 from ₹3.39 in the corresponding period last year.
👀 What to Watch
Investors should exercise caution as the company faces significant margin pressure and persistent losses in its API division. It is advisable to wait for signs of stabilization in the Agrochemicals business and improved profitability in the Pharma segment before considering new positions.
Shivalik Rasayan Q3 FY26 Consolidated Net Profit Drops 47% YoY to ₹3.67 Crore
Shivalik Rasayan reported a weak performance for the quarter ended December 31, 2025, with consolidated net profit declining 47.1% YoY to ₹3.67 crore. Total consolidated revenue fell 4.2% YoY to ₹83.21 crore, also showing a sequential decline of 11.7% from the previous quarter. The Agrochemicals segment faced significant margin pressure, with segment results falling from ₹718.61 lakhs to ₹592.72 lakhs YoY. The company's consolidated performance remains heavily dependent on its Pharma Formulations segment and its associate, Medicamen Biotech Limited.
Key Highlights
Consolidated Net Profit fell 47.1% YoY to ₹366.95 Lakhs from ₹693.79 Lakhs.
Consolidated Revenue from operations decreased to ₹8,203.75 Lakhs compared to ₹8,530.61 Lakhs in Q3 FY25.
Standalone Net Profit saw a sharp decline to ₹203.49 Lakhs from ₹401.59 Lakhs in the year-ago period.
Consolidated EPS for the quarter dropped significantly to ₹1.71 from ₹3.39 YoY.
Agrochemicals segment revenue stood at ₹2,810.56 Lakhs, while Pharma Formulations contributed ₹4,690.85 Lakhs to consolidated totals.
👀 What to Watch
Investors should exercise caution as the company is experiencing a significant contraction in both top-line and bottom-line growth. The sharp decline in EPS and segment margins suggests operational headwinds that may require a few quarters to stabilize.
